Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213447739> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W3213447739 endingPage "786" @default.
- W3213447739 startingPage "785" @default.
- W3213447739 abstract "Background: Vaccination strategies against SARS-CoV-2 have been implemented worldwide. Safety and effectiveness outcomes in special populations, such as MS patients receiving diseasemodifying therapy (DMT) may guide future recommendations. Objectives: To assess the safety and seroconversion (SC) rates of mRNA (Pfizer-BioNtech) and inactivated (Sinovac-CoronaVac) vaccines in patients with MS in Chile. Methods: Multicentric, prospective, observational study including patients from 4 tertiary centres. Humoral immune response was determined at least 4 weeks after the second dose of either vaccine, by assessing IgG against spike 1 (S1) and nucleocapsid (N) proteins (ECLIA Cobas, Roche) and events supposedly attributable to vaccination (AESAV) were collected. Subgroup comparisons according to DMT and type of vaccine were also performed. Results: A total of 115 patients were included (71% women, mean age 41+11 years, mean disease duration 8+6 years, 83% RRMS, median EDSS 2.0 (range 0-7.5)). Humoral immune response rates of the whole sample were 67% (100% for S1 and 16% for N). Thirty percent of the patients received mRNA vaccine, and SC was significantly higher in this group compared to the inactivated vaccine (81% vs. 61%, p=0.04). Interferon beta/ glatiramer acetate were used by 4% of the patients (100% SC), teriflunomide/dimethylfumarate 8% (100% SC), fingolimod 11% (92% SC), cladribine 7% (88% SC), natalizumab 6% (100% SC), ocrelizumab/rituximab 57% (45% SC, 58% with mRNA and 38% with inactivated vaccine), alemtuzumab 5% (100% SC), and 2% without DMT (100% SC). The most frequent AESAV were local pain (16%), myalgia (13%), headache (11%), and mild fever (3%). Two mild relapses with the inactivated vaccine were observed within the 8 weeks after the first dose. By the time of this report, 3 patients developed COVID- 19 after full vaccination (1 fingolimod, positive IgG-S1, mild COVID19;1 natalizumab, positive IgG-S1, mild COVID19;1 rituximab, negative IgG-S1, required hospitalization and 1 day of non-invasive mechanical ventilation). Conclusions: Vaccination with mRNA and inactivated vaccines appear to be safe in patients with MS, with less than 2% risk of relapse after vaccination. Higher seroconversion rates were observed using the mRNA vaccine. Humoral immune response rate is lower in patients using antiCD20. Determining cellular response and clinical effectiveness on preventing SARS-CoV-2 infection or severe COVID-19 is still needed to be determined." @default.
- W3213447739 created "2021-11-22" @default.
- W3213447739 creator A5007931736 @default.
- W3213447739 creator A5017903215 @default.
- W3213447739 creator A5019828513 @default.
- W3213447739 creator A5024288987 @default.
- W3213447739 creator A5054420589 @default.
- W3213447739 creator A5064152918 @default.
- W3213447739 creator A5064607083 @default.
- W3213447739 creator A5073634440 @default.
- W3213447739 creator A5082131396 @default.
- W3213447739 creator A5089148337 @default.
- W3213447739 date "2021-01-01" @default.
- W3213447739 modified "2023-09-26" @default.
- W3213447739 title "Safety and seroconversion rates of mRNA and inactivated vaccines against SARS-CoV-2 among patients with multiple sclerosis: A multicentric observational study" @default.
- W3213447739 hasPublicationYear "2021" @default.
- W3213447739 type Work @default.
- W3213447739 sameAs 3213447739 @default.
- W3213447739 citedByCount "0" @default.
- W3213447739 crossrefType "journal-article" @default.
- W3213447739 hasAuthorship W3213447739A5007931736 @default.
- W3213447739 hasAuthorship W3213447739A5017903215 @default.
- W3213447739 hasAuthorship W3213447739A5019828513 @default.
- W3213447739 hasAuthorship W3213447739A5024288987 @default.
- W3213447739 hasAuthorship W3213447739A5054420589 @default.
- W3213447739 hasAuthorship W3213447739A5064152918 @default.
- W3213447739 hasAuthorship W3213447739A5064607083 @default.
- W3213447739 hasAuthorship W3213447739A5073634440 @default.
- W3213447739 hasAuthorship W3213447739A5082131396 @default.
- W3213447739 hasAuthorship W3213447739A5089148337 @default.
- W3213447739 hasBestOaLocation W32134477391 @default.
- W3213447739 hasConcept C126322002 @default.
- W3213447739 hasConcept C159654299 @default.
- W3213447739 hasConcept C203014093 @default.
- W3213447739 hasConcept C22070199 @default.
- W3213447739 hasConcept C2776036978 @default.
- W3213447739 hasConcept C2777451964 @default.
- W3213447739 hasConcept C2777703276 @default.
- W3213447739 hasConcept C2778577042 @default.
- W3213447739 hasConcept C2778616394 @default.
- W3213447739 hasConcept C2779015954 @default.
- W3213447739 hasConcept C2780640218 @default.
- W3213447739 hasConcept C2780892749 @default.
- W3213447739 hasConcept C2781004633 @default.
- W3213447739 hasConcept C71924100 @default.
- W3213447739 hasConceptScore W3213447739C126322002 @default.
- W3213447739 hasConceptScore W3213447739C159654299 @default.
- W3213447739 hasConceptScore W3213447739C203014093 @default.
- W3213447739 hasConceptScore W3213447739C22070199 @default.
- W3213447739 hasConceptScore W3213447739C2776036978 @default.
- W3213447739 hasConceptScore W3213447739C2777451964 @default.
- W3213447739 hasConceptScore W3213447739C2777703276 @default.
- W3213447739 hasConceptScore W3213447739C2778577042 @default.
- W3213447739 hasConceptScore W3213447739C2778616394 @default.
- W3213447739 hasConceptScore W3213447739C2779015954 @default.
- W3213447739 hasConceptScore W3213447739C2780640218 @default.
- W3213447739 hasConceptScore W3213447739C2780892749 @default.
- W3213447739 hasConceptScore W3213447739C2781004633 @default.
- W3213447739 hasConceptScore W3213447739C71924100 @default.
- W3213447739 hasLocation W32134477391 @default.
- W3213447739 hasOpenAccess W3213447739 @default.
- W3213447739 hasPrimaryLocation W32134477391 @default.
- W3213447739 hasRelatedWork W3164069651 @default.
- W3213447739 hasRelatedWork W3182483970 @default.
- W3213447739 hasRelatedWork W3183775993 @default.
- W3213447739 hasRelatedWork W3186114398 @default.
- W3213447739 hasRelatedWork W3191594171 @default.
- W3213447739 hasRelatedWork W3198050578 @default.
- W3213447739 hasRelatedWork W3198576593 @default.
- W3213447739 hasRelatedWork W3204028165 @default.
- W3213447739 hasRelatedWork W3205543694 @default.
- W3213447739 hasRelatedWork W3206879504 @default.
- W3213447739 hasRelatedWork W3207555229 @default.
- W3213447739 hasRelatedWork W3211447907 @default.
- W3213447739 hasRelatedWork W3212319456 @default.
- W3213447739 hasRelatedWork W3212768616 @default.
- W3213447739 hasRelatedWork W3213468071 @default.
- W3213447739 hasRelatedWork W3213544097 @default.
- W3213447739 hasRelatedWork W3213769237 @default.
- W3213447739 hasRelatedWork W3214090994 @default.
- W3213447739 hasRelatedWork W3202588901 @default.
- W3213447739 hasRelatedWork W3210147089 @default.
- W3213447739 hasVolume "27" @default.
- W3213447739 isParatext "false" @default.
- W3213447739 isRetracted "false" @default.
- W3213447739 magId "3213447739" @default.
- W3213447739 workType "article" @default.